Engineering precision nanoparticles for drug delivery
Michael J. Mitchell,Margaret M. Billingsley,Rebecca M Haley,Marissa E. Wechsler,Nicholas A. Peppas,Robert Langer +5 more
Reads0
Chats0
TLDR
Advances in nanoparticle design that overcome heterogeneous barriers to delivery are discussed, arguing that intelligent nanoparticles design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.Abstract:
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers - systemic, microenvironmental and cellular - that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.read more
Citations
More filters
Journal ArticleDOI
Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement.
TL;DR: Liposomes, an early version of LNPs, are a versatile nanomedicine delivery platform for treatment of a variety of diseases, such as antitumor and nucleic acid therapeutics and vaccine delivery systems as mentioned in this paper.
Journal Article
T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
Daniela Schmid,Chun Gwon Park,Christina A. Hartl,Nikita Subedi,Adam N.R. Cartwright,Regina Bou Puerto,James Maiarana,Gordon J. Freeman,Kai W. Wucherpfennig,Michael S. Goldberg,Yiran Zheng,Darrell J. Irvine +11 more
TL;DR: PD-1-targeting nanoparticles containing a TGFβ inhibitor or a TLR7/8 agonist are used to deliver these payloads to T cells or via T cells to the tumor microenvironment, leading to anti-tumor efficacy in vivo.
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
Helen Lee,Anthony F. Shields,Barry A. Siegal,Kathy D. Miller,Ian E. Krop,Cynthia X. Ma,Patricia LoRusso,Pamela N. Munster,Karen Campbell,Daniel F. Gaddy,Shannon C. Leonard,Elena Geretti,Stephanie J. Blocker,Dmitri B. Kirpotin,Victor Moyo,Thomas Wickham,Bart S. Hendriks +16 more
TL;DR: Findings provide important evidence and quantification of the EPR effect in human metastatic tumors and support imaging nanoparticle deposition in tumors as a potential means to identify patients well suited for treatment with therapeutic nanoparticles.
Journal ArticleDOI
Role of nanotechnology behind the success of mRNA vaccines for COVID-19.
Amit Khurana,Prince Allawadhi,Isha Khurana,Sachin Allwadhi,Ralf Weiskirchen,Anil Kumar Banothu,Deepak Chhabra,Kamaldeep Joshi,Kala Kumar Bharani +8 more
TL;DR: The emergency use authorization (EUA) by the US-FDA for two mRNA-based vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) has brought hope of addressing the COVID-19 pandemic which has killed more than two million people globally as mentioned in this paper.
Journal Article
Microfluidic Mixing: A General Method for Encapsulating Macromolecules in Lipid Nanoparticle Systems B
TL;DR: It is shown that LNP-siRNA systems can exhibit progressively more bilayer structure as the proportion of bilayer DSPC lipid is increased, suggesting that the core of LNPs can exhibit a continuum of nanostructures depending on the proportions and structural preferences of component lipids.
References
More filters
Journal ArticleDOI
Target delivery selective CSF-1R inhibitor to tumor-associated macrophages via erythrocyte-cancer cell hybrid membrane camouflaged pH-responsive copolymer micelle for cancer immunotherapy
TL;DR: In vitro and in vivo studies demonstrated the therapeutical potential of DH@ECm for tumor immunotherapy, which possessed pH-responsive characteristic and unique "membrane escape effect" to facilitate recognition and internalization by TAMs via dextran-CD206 receptor specific interaction.
Journal ArticleDOI
pH/Redox Dual-Responsive Polyplex with Effective Endosomal Escape for Codelivery of siRNA and Doxorubicin against Drug-Resistant Cancer Cells.
TL;DR: The polyplex with effective endo-lysosomal escape provides a rational approach for codelivery of siRNAs and chemotherapy agents for MDR reversal.
Journal ArticleDOI
A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics.
TL;DR: The results strongly suggest that PK metrics and calculations can influence the interpretation of NP tumor delivery and stress the need to properly validate novel PK metrics against traditional approaches.
Journal ArticleDOI
Messenger RNA therapy for rare genetic metabolic diseases.
TL;DR: The preclinical evidence supporting the potential of liver-mediated mRNA therapy for three rare genetic conditions: methylmalonic acidaemia, acute intermittent porphyria and ornithine transcarbamylase deficiency is discussed.
Journal ArticleDOI
The application of nanotechnology in immune checkpoint blockade for cancer treatment
Huan Deng,Zhiping Zhang +1 more
TL;DR: The basic mechanisms of the immune checkpoint pathways are introduced and the recent successes of immune checkpoint blockade (ICB) therapy in combination with nanoparticle delivery system are outlined and the potential of nanotechnology to enhance immune checkpoint therapeutic efficacy is discussed.
Related Papers (5)
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra,Gitishree Das,Leonardo Fernandes Fraceto,Leonardo Fernandes Fraceto,Estefania Vangelie Ramos Campos,Estefania Vangelie Ramos Campos,Maria del Pilar Rodriguez-Torres,Laura Susana Acosta-Torres,Luis A. Diaz-Torres,Renato Grillo,Mallappa Kumara Swamy,Shivesh Sharma,Solomon Habtemariam,Han-Seung Shin +13 more